URGN
UroGen Pharma Ltd
41.40$
+0.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -328.5% | – | – | – | – | – | – | – | – | |
| – | +66.7% | +276.7% | +88.5% | -2.8% | +101.4% | +217.5% | +54.4% | -13.3% | +2.5% | -6.2% | -30.4% | +103.3% | |
| – | -45.8% | +53.2% | +338.1% | +220.3% | +386.4% | -2.2% | -6.5% | -17.5% | -54.2% | -11.7% | +40.3% | -8.8% | |
| – | -53.4% | +1,801.6% | -1.8% | +37.4% | +375.3% | -2.5% | -10.2% | -14.2% | -50.5% | – | – | – | |
| – | -1,346.2% | – | +98.7% | +210.5% | +90.7% | -39.7% | -247.4% | – | – | – | +47.9% | -665.9% | |
| – | -57.9% | +1,154.2% | +130.9% | -61.0% | +106.6% | -42.0% | +273.8% | -38.1% | -66.2% | -23.6% | +52.1% | -2.0% | |
| – | -98.9% | +30,000.0% | +163.5% | +4,487.3% | – | -512.6% | – | -95.6% | -73.9% | -189.9% | +2,063.0% | – | |
| – | +1,666.0% | -64.8% | -97.4% | +10,711.8% | +8.1% | +148.0% | -90.0% | -100.5% | – | – | – | – | |
| – | +0.0% | – | – | – | – | – | – | -100.0% | – | -100.0% | – | -107.6% | |
| – | +42.8% | +335.9% | -100.0% | – | +7.9% | +148.8% | -90.0% | +337.6% | +34.3% | +20.4% | +66.4% | -79.5% | |
| – | +1.3% | +1,593.3% | -76.0% | +361.7% | +311.7% | -179.8% | – | -319.2% | – | +272.4% | +95.0% | -178.9% | |
| – | – | – | – | -381.7% | – | – | – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.